Should experimental therapy be made available off-study for terminally ill patients?

Lancet Oncology

Volumn 7, Issue 7, 2006, Pages 531-533

  Davis, Mellar P ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NEW DRUG;

CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; DELIRIUM; DEPRESSION; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; EXPERIMENTAL THERAPY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE QUALITY; HOPE; HUMAN; INFORMED CONSENT; INTERPERSONAL COMMUNICATION; LETTER; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MEDICAL ETHICS; MEDICOLEGAL ASPECT; OUTCOME ASSESSMENT; PATIENT DECISION MAKING; PATIENT RIGHT; PHYSICIAN ASSISTANT ATTITUDE; PRIORITY JOURNAL; QUALITY OF LIFE; SUBSTANCE ABUSE; TERMINAL CARE; TERMINALLY ILL PATIENT; TREATMENT OUTCOME; UNITED STATES; VOLUNTARY EUTHANASIA;

DRUGS, INVESTIGATIONAL; HUMANS; LEGISLATION, DRUG; TERMINALLY ILL; UNITED STATES;

EID: 33745258679     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(06)70737-9     Document Type: Letter

References (14)

1. US Court of Appeals. Abigail Alliance for Better Access to Developmental Drugs vs Andrew C von Eschenbach, MD and Michael O Leavitt. No. 04-5350. May 2, 2006, decision. http://pacer.cadc.uscourts.gov/docs/common/opinions/200605/04-5350a.pdf (accessed June 9, 2006)
2. Debate. Should patients be able to choose physician-assisted suicide at the end of their lives?. Lancet Oncol 7 (2006) 600-602
3. Parker M. Medicalizing meaning: demoralization syndrome and the desire to die. Aust N Z J Psychiatry 38 (2004) 765-773
4. Gill C. Depression in the context of disability and the "right to die". Theor Med Bioethics 25 (2004) 171-198
5. Werth J. The relationships among clinical depression, suicide, and other actions that may hasten death. Behav Sci Law 22 (2004) 627-649
6. Tattersall M., Gattellari M., Voigt K., and Butow P. When the treatment goal is not a cure: are patients informed adequately?. Support Care Cancer 10 (2002) 314-321
7. de Haes H., and Koedoot N. Patient centered decision making in palliative cancer treatment: a world of paradoxes. Patient Educ Couns 50 (2003) 43-49
8. Jansen S., Kievit J., Nooij M., et al. Patients' preferences for adjuvant chemotherapy in early stage breast cancer: is treatment available?. Br J Cancer 84 (2001) 1557-1585
9. Palda V., Llewellyn-Thomas H., Mackenzie R., et al. Breast cancer patients' attitudes about rationing post lumpectomy radiation therapy: applicability of trade-off methods to policy making. J Clin Oncol 15 (1997) 3192-3200
10. Fagerlin A., Zikmund-Fisher B., and Ubel P. Cure me even if it kills me: preferences for invasive cancer treatment. Med Decis Making 25 (2005) 614-619
11. Katz R. FDA: evidentiary standards for drug development and approval. NeuroRx 1 (2004) 307-316
12. Krantz J. New drugs and the Kefauver-Harris Amendment. J New Drugs 6 (1966) 77-79
13. Colodner L. The US Food and Drug Administration Modernization Act of 1997: impact on consumers. Clin Therap 20 (1998) C20-C25
14. Cruzan v Director, Missouri Department of Health, 497 vs 261: 1990.